Notes on Insulin Signaling, Receptors, and Type 2 Diabetes
Insulin synthesis, processing, and circulating markers
Insulin is a polypeptide produced in the pancreatic beta cells and is processed intracellularly from a larger precursor called proinsulin. During processing, a segment known as C peptide is cleaved from proinsulin and released together with insulin. C peptide is much more stable in the circulation than insulin, which has a short half-life, so C peptide serves as a useful proxy for measuring insulin secretion. This relationship highlights that insulin secretion can be inferred from circulating C peptide levels, especially since insulin itself is rapidly cleared from the bloodstream.
Insulin receptor structure and membrane localization
Insulin receptors are expressed on hepatocytes (liver), skeletal muscle, and adipocytes. They are integral membrane proteins—meaning they span the cell membrane and have domains both outside and inside the cell. The receptor is a heterotetramer composed of two alpha subunits and two beta subunits, arranged so that insulin binds to the extracellular alpha subunits. Binding induces a conformational disturbance that brings the intracellular domains of the receptor into closer proximity, which is crucial for initiating the intracellular signaling cascade. The insulin receptor itself functions as an enzyme on the inside of the cell, possessing tyrosine kinase activity that becomes activated upon receptor engagement.
The insulin receptor tyrosine kinase reaction
Insulin receptor signaling begins with the receptor’s tyrosine kinase activity. The receptor phosphorylates substrate proteins on specific tyrosine residues. A classic illustration of the core reaction is that ATP serves as the phosphate donor: a phosphate from ATP is transferred to a tyrosine hydroxyl group on a substrate, producing a phosphotyrosine and ADP. A representative schematic form of this reaction is
This phosphorylation event can occur on the insulin receptor itself (auto-phosphorylation) and on downstream signaling proteins such as IRS-1, IRS-2, and SHC, setting the stage for further signal propagation.
Primary substrates: IRS and SHC; distinct roles
Following auto-phosphorylation, adaptor proteins bind to the phosphorylated receptor. Two key adaptor proteins are insulin receptor substrate 1 (IRS-1) and IRS-2 (and also IRS-3, IRS-4 in other tissues). IRS proteins largely modulate metabolic responses (e.g., glucose uptake, lipid synthesis), whereas SHC is more linked to cell proliferation and differentiation. In short, IRS-1/IRS-2 predominantly drive metabolic actions, while SHC contributes to growth-related signaling.
Core signaling cascade: PI3K, PIP3, PDK1, and AKT
A central axis of insulin signaling involves phosphatidylinositol 3-kinase (PI3K), which phosphorylates membrane phospholipids near the inner leaflet of the plasma membrane. Specifically, the phosphorylation reaction converts phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5-trisphosphate:
This hyperphosphorylated lipid, PI(3,4,5)P extsubscript{3}, serves as a docking site that recruits downstream kinases to the membrane, including protein kinase B (AKT) and 3-phosphoinositide-dependent protein kinase-1 (PDK1). The generation of PI extsubscript{3} is therefore a pivotal step that translates receptor activation into intracellular responses.
As PI3K produces PI(3,4,5)P extsubscript{3}, this lipid activates PDK1 and AKT. AKT is a serine/threonine kinase that orchestrates many metabolic effects, and its activation requires phosphorylation events coordinated by PDK1 and other kinases. The membrane-localized activation of AKT leads to downstream metabolic actions that alter cellular and whole-body metabolism.
Visualizing the signaling architecture and tissue context
A simplified view shows insulin at the top binding its receptor on the cell surface. The receptor engages SHC and IRS proteins, which channel signals to distinct downstream branches. The upstream portion—receptor, auto-phosphorylation, IRS/SHC docking, and PI3K activation—constitutes a relatively straightforward signaling module that governs lipid synthesis, glucose transport, and general metabolic regulation. In parallel, SHC-related signaling interfaces with proliferative pathways, illustrating that insulin signaling can influence both metabolism and growth, depending on the tissue context and adaptor usage.
Different tissues express distinct IRS isoforms. In adipose tissue, skeletal muscle, and liver, IRS-1 and IRS-2 are the major mediators of insulin action. IRS-3 and IRS-4 contribute to modulation but are not as critical as IRS-1 and IRS-2. This tissue-specific isoform expression helps explain variations in insulin sensitivity and metabolic responses among tissues and across developmental stages.
Downstream effects: metabolic outcomes vs growth signals
In terms of metabolic responses, the signaling axis downstream of AKT influences several processes: increasing glucose uptake in muscle and fat, promoting lipid synthesis, and enhancing glycogen storage. AKT and its targets facilitate these metabolic changes, helping cells and tissues manage glucose and energy homeostasis. Separately, the SHC module ties into proliferative and differentiative programs, illustrating how insulin signaling can influence cell growth, not just metabolism. The transcript notes a set of upstream “generic” signaling enzymes (e.g., PI3K, PDK1, AKT) and a downstream group of “response-specific” enzymes that tailor the cellular response toward either metabolic or growth-related outcomes.
Insulin receptor substrates, tissue distribution, and functional hierarchy
Insulin receptor substrates (IRS) and SHC are central hubs that connect receptor activation to downstream kinases. The expression pattern of IRS isoforms across tissues underlines the concept of tissue-specific insulin action. IRS-1 and IRS-2 are the dominant mediators of insulin signaling in many tissues. IRS-3 and IRS-4 provide modulatory roles but are less critical in orchestrating insulin’s core metabolic actions. Tissue distribution includes fat cells, skeletal muscle, liver, brain (including the hypothalamus), and the pancreatic islet beta cells, reflecting the broad influence of insulin signaling on energy balance and metabolism through diverse cellular contexts.
Hormone resistance in type 2 diabetes: practical implications of signaling defects
The notes introduce several features of insulin resistance characteristic of type 2 diabetes. Key points include reduced uptake of glucose by muscle and adipose tissue, which deprives these tissues of glucose and contributes to systemic hyperglycemia. There is also enhanced hepatic glucose production due to increased gluconeogenesis and impaired glycogen storage, which further raises plasma glucose levels. The pancreas responds with hyperinsulinemia as beta cells attempt to compensate by producing more insulin, but this compensatory mechanism eventually fails, leading to beta-cell dysfunction and progression of diabetes. These points connect the signaling pathway to a clinical phenotype: impaired insulin action at the level of receptor signaling and downstream effectors drives the dysregulated glucose homeostasis observed in type 2 diabetes.
Connecting to broader principles and future topics
The insulin signaling pathway exemplifies how extracellular hormones trigger receptor tyrosine kinases, propagate signals through adaptor proteins, and mobilize second messengers at the membrane to effect broad cellular changes. It illustrates the tight coupling between receptor-level events, intracellular kinase cascades, and tissue-specific outcomes. The forthcoming discussion (in the next mini lecture) will explore the origins of insulin resistance in more depth, focusing on how perturbations at multiple nodes of this pathway contribute to type 2 diabetes and how these insights inform therapeutic strategies and research directions.
Practical and ethical considerations (contextual note)
While the transcript centers on molecular signaling, the practical implications are substantial: understanding how insulin resistance arises informs prevention, diagnosis, and treatment of type 2 diabetes, which has major public health implications given its rising prevalence. Therapeutic approaches often target improving insulin sensitivity, enhancing insulin signaling in muscle and liver, or preserving beta-cell function, underscoring the translational relevance of these molecular insights. The ethical dimension—such as ensuring equitable access to advances in diabetes care and addressing disparities in disease burden—emerges when applying these mechanistic insights to real-world populations, though explicit ethical discussion is not provided in the lecture content itself.
Summary of core concepts (quick reference)
Insulin is produced as proinsulin in pancreatic beta cells; C peptide is cleaved and serves as a stable marker of insulin secretion.
Insulin receptors are heterotetramers with two alpha and two beta subunits; they are membrane-bound tyrosine kinases that undergo auto-phosphorylation upon insulin binding.
The receptor phosphorylates tyrosine residues on itself and on downstream substrates such as IRS-1, IRS-2, and SHC.
IRS-1/IRS-2 are the primary mediators of metabolic signaling; SHC links to proliferative/differentiation pathways.
PI3K, which phosphorylates PI(4,5)P extsubscript{2} to PI(3,4,5)P extsubscript{3}, is a pivotal step that recruits PDK1 and AKT to the membrane:
Activation of AKT promotes metabolic actions such as glucose uptake and lipid synthesis, while SHC-associated signaling supports growth and differentiation.
Insulin resistance in type 2 diabetes features reduced glucose uptake in muscle and fat, increased hepatic glucose production via gluconeogenesis, impaired glycogen storage, hyperinsulinemia, and eventual beta-cell failure, forming the basis for future exploration of disease origins and interventions.